Unlocking the potential of Arjo

Arjo outlined a new strategy targeting an approximately SEK 350 million EBIT improvement versus 2025 by mid-2029. The plan centers on a more customer-focused operating model, deeper penetration of underpenetrated segments, tighter portfolio priorities, and improved use of capabilities across markets and functions. The target signals a meaningful medium-term profitability improvement, though execution will be key.

Analysis

The key underwriting question is not the 2029 EBIT endpoint but the conversion path: a 350 MSEK uplift likely requires a mix of commercial productivity, SKU rationalization and overhead leverage rather than purely cyclical volume recovery. The market should initially assign only partial credit because the target is long-dated; valuation rerating will depend on evidence within the next 2-4 quarters that order growth, gross margin and SG&A-to-sales are moving in tandem. A customer-centric model can improve installed-base monetization and service attachment, but it may also require near-term selling-system investment that suppresses the first year of incremental margin.

Arjo's defensible opportunity is in lifting utilization of its installed base and deepening penetration where clinical workflow and patient-handling requirements create switching costs. That favors recurring consumables, rentals and service revenue over a simple equipment-volume thesis, potentially reducing earnings volatility if execution succeeds. The competitive response risk is that larger medtech and hospital-equipment peers use bundled contracts or pricing concessions to protect accounts, limiting the ability to retain all of the stated EBIT benefit through price/mix.

Consensus may overreact to the absolute target without discounting delivery risk: a mid-2029 goal provides management substantial timing flexibility, and the announcement alone does not establish whether improvements are structural or dependent on favorable hospital capital-spending cycles. The near-term catalyst is a quantified bridge at subsequent reporting—especially disclosed restructuring costs, segment-level growth, price/mix and service penetration. Thesis is falsified if sales growth remains below inflation while SG&A rises, or if management cannot show a credible annualized run-rate improvement by FY2027.

Key Decisions for Investors

• Maintain ARJO.B as a watch-to-accumulate rather than chase the CMD reaction; initiate only after the next two results show simultaneous gross-margin expansion and declining SG&A as a percentage of sales. Target a 12-18 month holding period, with the position sized for execution risk rather than the full 2029 EBIT outcome.
• For an existing ARJO.B long, require management to quantify the 350 MSEK bridge between pricing/mix, volume, procurement and cost actions at the next reporting event. Reduce exposure if restructuring and commercial-investment costs absorb the expected first-year savings without an offsetting order or service-revenue acceleration.
• Use a relative-value framework versus broader European medtech exposure: long ARJO.B only if its EBIT-margin trajectory begins to outperform relevant hospital-equipment peers over the next 12 months; otherwise the long-duration target is unlikely to justify a sustained multiple premium.
• Set a FY2027 checkpoint: absent a visible annualized margin-improvement run rate of roughly one-third to one-half of the total target by then, treat the 2029 objective as low-confidence and exit any strategy-driven overweight.